THIS WEEK'S FEATURE
Titan Pharmaceuticals’ (NASDAQ:TTNP) relaunch of its Probuphine implant for the long-term maintenance treatment of opioid use disorder (OUD) demonstrated promising results with a meaningful increase in product shipments in the second half of 2018.
BeyondSpring (NASDAQ:BYSI) is preparing to file NDAs with the China FDA during the next six months for its lead asset, first-in-class agent Plinabulin, for the treatment of non-small cell lung cancer (NSCLC) and prevention of chemotherapy-induced neutropenia (CIN), with hopes for regulatory approvals of both indications before the end of 2019.
iBio (NYSE American:IBIO) has developed an industry-leading plant-based gene-expression technology to rapidly produce high levels of proteins used for making biologics at its contract development and manufacturing organization (CDMO) plant at College Station, Tex.
Canopy Health Innovations, the research subsidiary of Canopy Growth (TSX:WEED; NYSE:CGC) that focuses on the development of therapeutic and natural health cannabis products, will get a big boost from a blockbuster $5-billion (Canadian) investment by Constellation Brands (NYSE:STZ) in Canopy Growth, a world-leading diversified cannabis and hemp company.
Closely-held Zuga Medical expects to roll out its digital dental implant solution, known as ZugaLink, across the U.S. in 2019.